Associations between myeloperoxidase and paraoxonase-1 and type 2 diabetes in patients with ischemic heart disease.

Humans Antioxidants / metabolism Aryldialkylphosphatase / metabolism Cross-Sectional Studies Diabetes Mellitus, Type 2 / complications Lipoproteins, HDL / metabolism Myocardial Ischemia / complications Peroxidase
Dysfunctional high-density lipoprotein Ischemic heart disease Myeloperoxidase (MPO) Paraoxonase-1 (PON-1) Type 2 diabetes

Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
03 12 2022
Historique:
received: 06 12 2021
accepted: 31 10 2022
entrez: 3 12 2022
pubmed: 4 12 2022
medline: 7 12 2022
Statut: epublish

Résumé

The phrase "dysfunctional high-density lipoprotein" has been developed in the literature to describe the particle which loses its basic role- anti-oxidative and anti-inflammatory activity. In this porcess, the significance of enzymes- pro-oxidant myeloperoxidase (MPO) and antioxidant paraoxonase-1 (PON-1) from the perspective of HDL-C function has been noted. The objective of this study was to analyze the associations between two enzymes -MPO and PON-1 and type 2 diabetes (T2DM) in patients with ischemic heart disease (IHD). An observational cross-sectional study including 70 patients with IHD of whom 35 had also T2DM, and 35 had no T2DM. Laboratory tests (MPO, PON-1, fasting glucose, glycated hemoglobin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, and high-sensitivity C-reactive protein) were performed. The study revealed a significant difference in the serum concentration of the enzymes between patients with IHD with and without T2DM. Our results showed increased MPO concentration levels in diabetic patients. The analysis also revealed that T2DM is independently associated with an increase in MPO levels. Simultaneously, a decrease in PON-1 levels was observed in patients with T2DM. The study also revealed that T2DM is independently associated with a decrease in PON-1 levels. In patients with type 2 diabetes the profile of enzymes involved in high-density lipoprotein metabolism in patients with IHD is worse than in patients without T2DM. The increase in the levels of MPO, an enzyme with oxidative and atherogenic properties and on a decrease in PON-1 levels, an enzyme with antioxidant and atheroprotective properties is observed.

Sections du résumé

BACKGROUND
The phrase "dysfunctional high-density lipoprotein" has been developed in the literature to describe the particle which loses its basic role- anti-oxidative and anti-inflammatory activity. In this porcess, the significance of enzymes- pro-oxidant myeloperoxidase (MPO) and antioxidant paraoxonase-1 (PON-1) from the perspective of HDL-C function has been noted.
AIMS
The objective of this study was to analyze the associations between two enzymes -MPO and PON-1 and type 2 diabetes (T2DM) in patients with ischemic heart disease (IHD).
METHODS
An observational cross-sectional study including 70 patients with IHD of whom 35 had also T2DM, and 35 had no T2DM. Laboratory tests (MPO, PON-1, fasting glucose, glycated hemoglobin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, and high-sensitivity C-reactive protein) were performed.
RESULTS
The study revealed a significant difference in the serum concentration of the enzymes between patients with IHD with and without T2DM. Our results showed increased MPO concentration levels in diabetic patients. The analysis also revealed that T2DM is independently associated with an increase in MPO levels. Simultaneously, a decrease in PON-1 levels was observed in patients with T2DM. The study also revealed that T2DM is independently associated with a decrease in PON-1 levels.
CONCLUSIONS
In patients with type 2 diabetes the profile of enzymes involved in high-density lipoprotein metabolism in patients with IHD is worse than in patients without T2DM. The increase in the levels of MPO, an enzyme with oxidative and atherogenic properties and on a decrease in PON-1 levels, an enzyme with antioxidant and atheroprotective properties is observed.

Identifiants

DOI: 10.1186/s12872-022-02928-8 PMID: 36463116 PMC: PMC9719221
pubmed: 36463116
doi: 10.1186/s12872-022-02928-8
pii: 10.1186/s12872-022-02928-8
pmc: PMC9719221
doi:

Substances chimiques

Antioxidants 0
Aryldialkylphosphatase EC 3.1.8.1
Lipoproteins, HDL 0
Peroxidase EC 1.11.1.7
PON1 protein, human EC 3.1.8.1
MPO protein, human EC 1.11.1.7

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

521

Informations de copyright

© 2022. The Author(s).

Références

Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Metabolism. 2006 Sep;55(9):1201-6
pubmed: 16919539
J Am Coll Cardiol. 2010 Mar 16;55(11):1102-9
pubmed: 20223364
Antioxidants (Basel). 2020 Jul 29;9(8):
pubmed: 32751395
Curr Atheroscler Rep. 2010 Sep;12(5):343-8
pubmed: 20506005
Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):18-24
pubmed: 29168398
J Clin Epidemiol. 2003 Dec;56(12):1163-9
pubmed: 14680666
Curr Pharm Des. 2019;25(29):3128-3146
pubmed: 31470782
Curr Med Chem. 2019;26(9):1610-1630
pubmed: 29546829
Curr Med Chem. 2019;26(9):1644-1664
pubmed: 29848265
Biochim Biophys Acta. 2012 Mar;1821(3):490-501
pubmed: 22178192
J Clin Endocrinol Metab. 2005 Mar;90(3):1728-33
pubmed: 15613429
J Physiol Pharmacol. 2019 Dec;70(6):
pubmed: 32084643
Exp Clin Endocrinol Diabetes. 2016 Jan;124(1):49-54
pubmed: 26797862
Diabetes Metab Syndr. 2013 Apr-Jun;7(2):108-11
pubmed: 23680251
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):396-400
pubmed: 30641731
Mol Cell Biochem. 2018 Mar;440(1-2):167-187
pubmed: 28828539
Sci Rep. 2020 Apr 10;10(1):6170
pubmed: 32277104
Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):613-9
pubmed: 19201174
Antioxidants (Basel). 2019 Jul 11;8(7):
pubmed: 31336709
Curr Cardiol Rep. 2017 Nov 4;19(12):132
pubmed: 29103089
J Biol Chem. 2012 Feb 24;287(9):6375-86
pubmed: 22219194
Indian J Physiol Pharmacol. 2014 Jan-Mar;58(1):13-6
pubmed: 25464671
Nat Rev Cardiol. 2016 Jan;13(1):48-60
pubmed: 26323267
Diabetes Metab Syndr. 2016 Apr-Jun;10(2 Suppl 1):S123-6
pubmed: 27016886
Curr Opin Lipidol. 2003 Aug;14(4):353-9
pubmed: 12865732
Oxid Med Cell Longev. 2019 Aug 14;2019:3085756
pubmed: 31485289
Physiol Rev. 2005 Oct;85(4):1343-72
pubmed: 16183915
JAMA. 2013 Sep 4;310(9):948-59
pubmed: 24002281
Dis Markers. 2015;2015:761939
pubmed: 26451069
JAMA. 2001 Nov 7;286(17):2136-42
pubmed: 11694155
Atherosclerosis. 2017 Aug;263:156-162
pubmed: 28645072
Atherosclerosis. 2013 Dec;231(2):308-14
pubmed: 24267244
Diabetes Care. 2019 Jan;42(Suppl 1):S7-S12
pubmed: 30559227

Auteurs

Katarzyna Nessler (K)

Department of Family Medicine, Chair of Internal Medicine and Gerontology, Jagiellonian University Medical College in Krakow, 4 Bochenska str, 31-061, Krakow, Poland. katarzynanessler@gmail.com.

Rafal Grzybczak (R)

Department of Cardiac Rehabilitation, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka str, 31-202, Krakow, Poland.

Michal Nessler (M)

Burns and Plastic Surgery Centre of Malopolska, Rydygier Memorial Hospital, Os. Zlotej Jesieni 1, 31-826, Krakow, Poland.

Jarosław Zalewski (J)

Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, 80 Pradnicka str, 31-202, Krakow, Poland.

Grzegorz Gajos (G)

Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, 80 Pradnicka str, 31-202, Krakow, Poland.

Adam Windak (A)

Department of Family Medicine, Chair of Internal Medicine and Gerontology, Jagiellonian University Medical College in Krakow, 4 Bochenska str, 31-061, Krakow, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Associations between myeloperoxidase and...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Agents protecteurs › Antioxydants › Associations between myeloperoxidase and...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Phosphoric triester hydrolases › Aryldialkylphosphatase › Associations between myeloperoxidase and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Associations between myeloperoxidase and...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Associations between myeloperoxidase and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Lipoprotéines HDL › Associations between myeloperoxidase and...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Ischémie myocardique › Associations between myeloperoxidase and...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Peroxidases › Myeloperoxidase › Associations between myeloperoxidase and...